Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022

A nationwide survey of SARS-CoV-2 antinucleocapsid seroprevalence among blood donors in Japan revealed that, as of November 2022, infection-induced seroprevalence of the population was 28.6% (95% CI 27.6%–29.6%). Seroprevalence studies might complement routine surveillance and ongoing monitoring eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Ryo, Arashiro, Takeshi, Kitamura, Noriko, Arai, Satoru, Takahashi, Koki, Suzuki, Tadaki, Suzuki, Motoi, Yoneoka, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2023
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461656/
https://www.ncbi.nlm.nih.gov/pubmed/37506681
http://dx.doi.org/10.3201/eid2909.230365
Descripción
Sumario:A nationwide survey of SARS-CoV-2 antinucleocapsid seroprevalence among blood donors in Japan revealed that, as of November 2022, infection-induced seroprevalence of the population was 28.6% (95% CI 27.6%–29.6%). Seroprevalence studies might complement routine surveillance and ongoing monitoring efforts to provide a more complete real-time picture of COVID-19 burden.

Ejemplares similares